Queensland biotechnology company Microbio expects clinical evaluation trials of its InfectID-BSI tests to be completed next month, prior to launching in the European market.
US based Landrich Group is managing the trials at four locations in the USA, South America, India and Australia, undertaking a performance evaluation of Microbio InfectID assays.
Read more in the media release: 220412_Independent assessment of Microbio’s BSI test expected to be completed in May
Microbio is pleased to announce that following positive domestic pilot study results, its market entry plans for its flagship InfectID-BSI test, which has the potential for significant improvement in detecting bloodstream infection and sepsis, the world’s biggest killer.
Bloodstream infection (BSI) and sepsis result in 11 million deaths annually, killing more people than all forms of
cancer. InfectID-BSI is an in vitro diagnostic test which significantly improves patient outcomes by telling clinicians
within three hours of taking a blood sample which infection to treat.
Read more in the media release: 220328_Microbio_announces_capital_raise_to_launch_revolutionary_bloodstream_infection_test_in_Europe